Indeed, you're right about that ...
I don't know just how novel ENZC's methodology for discovering (patentable) immutable sites is or how valuable those sites might be (IP), but Dr. Chandra did say their process is "unique" and that no else has done it before. (That said, AI has been used in biotech going as far back as the 90s.)
The value of those immutable sites will be determined by whether or not ENZC can develop safe and effective treatments/cures, or if other pharma companies are keen on buying or licensing ENZC's IP (likely dependent on certain development milestones). Hopefully, Samsung can help ENZC expedite the arduous process to clinical trials, starting from cell line development of their mAbs through regulatory filings and IND. I don't imagine that will be done before Q2 2022, so my eyes are on ITV-1 as the nearest candidate for clinical trials, and audited financials along with application to QB as the next catalyst.
News 
Market Data 
Discover 
